Latest Share Chat

CLIN.L Share News (CLIN)

CLIN.L Information

There is currently no data for CLIN

Clinigen holds earnings growth guidance after solid first half

Wed, 12th Jan 2022 11:13

(Alliance News) - Clinigen Group PLC reiterated its annual earnings forecast on Wednesday after a "solid performance" in its first half but warned of the continued risks presented by the Covid-19 Omicron variant.

"During the first half of the year we have seen a solid performance across both the Services and Products divisions," commented Chief Executive Shaun Chilton.

The Staffordshire-based pharmaceuticals and services provider expects financial year 2022 earnings before interest, tax, depreciation and amortisation growth of between 5% and 10%.

"We remain mindful of the continued prevalence of the Covid-19 Omicron variant, which has the potential to impact our principal markets. However, we continue to perform well on those elements within our control and remain focused on building the lifecycle platform to service the needs of pharma companies and healthcare professionals around the globe," added Chilton.

Shares were 0.4% lower at 918.61 pence on Wednesday morning in London.

By Will Paige; willpaige@alliancenews.com

More News

1 Apr 2022 20:22

IN BRIEF: UK court sanctions Titon takeover of Clinigen

Clinigen Group PLC - Burton On Trent, Staffordshire-based pharmaceutical services - Says Thursday that its takeover by Triton Investment Management Ltd has been sanctioned by the High Court of Justice in England and Wales. Shares will be cancelled from trading on AIM on Tuesday.

23 Feb 2022 19:06

TRADING UPDATES: IPF swings to profit; Seraphine lowers outlook

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

23 Feb 2022 13:28

Clinigen revenue rises as shareholders approve its acquisition

(Sharecast News) - Pharmaceuticals and service company Clinigen Group reported a 10% improvement in net revenue from continuing operations in its half-year results on Wednesday, or 14% on an organic basis, to £238.1m.

16 Feb 2022 10:09

IN BRIEF: Clinigen expects acquisition by Triton to complete in April

Clinigen Group PLC - Burton On Trent, Staffordshire-based pharmaceutical services - Says its acquisition by funds managed by Triton Investment Management Ltd is likely to complete in early April, with its shares due to be cancelled on AIM on April 5. The deal and timeline are subject to antitrust and foreign investment approvals. Triton, a private equity firm submitted a cash offer of 925 pence per share, valuing Clinigen at GBP1.3 billion, which was approved by shareholders last Tuesday. The latest date for completion is September 8.

9 Feb 2022 10:38

IN BRIEF: Clinigen signs global distribution deal for Qinlock

8 Feb 2022 14:41

IN BRIEF: Clinigen shareholders approve takeover by Triton funds

17 Jan 2022 10:05

Triton increases takeover bid for Clinigen to GBP1.3 billion

17 Jan 2022 07:29

Triton makes 'increased and final' 925p bid for Clinigen

(Sharecast News) - Clinigen announced an increased and final all-cash offer from Triton of 925p per share on Monday.

12 Jan 2022 11:49

Clinigen reiterates guidance after 'solid' first half

(Sharecast News) - Pharmaceutical products and services company Clinigen reiterated its guidance for EBITDA growth in the 2022 financial year of between 5% and 10% in a trading update on Wednesday.

11 Jan 2022 14:59